EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document 32016R1086
Commission Implementing Regulation (EU) 2016/1086 of 5 July 2016 approving 2-bromo-2-(bromomethyl)pentanedinitrile (DBDCB) as an existing active substance for use in biocidal products of product-type 6 (Text with EEA relevance)
Commission Implementing Regulation (EU) 2016/1086 of 5 July 2016 approving 2-bromo-2-(bromomethyl)pentanedinitrile (DBDCB) as an existing active substance for use in biocidal products of product-type 6 (Text with EEA relevance)
Commission Implementing Regulation (EU) 2016/1086 of 5 July 2016 approving 2-bromo-2-(bromomethyl)pentanedinitrile (DBDCB) as an existing active substance for use in biocidal products of product-type 6 (Text with EEA relevance)
C/2016/4104
OJ L 180, 6.7.2016, p. 15–17
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
In force
|
6.7.2016 |
EN |
Official Journal of the European Union |
L 180/15 |
COMMISSION IMPLEMENTING REGULATION (EU) 2016/1086
of 5 July 2016
approving 2-bromo-2-(bromomethyl)pentanedinitrile (DBDCB) as an existing active substance for use in biocidal products of product-type 6
(Text with EEA relevance)
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (1), and in particular the third subparagraph of Article 89(1) thereof,
Whereas:
|
(1) |
Commission Delegated Regulation (EU) No 1062/2014 (2) establishes a list of existing active substances to be evaluated for their possible approval for use in biocidal products. That list includes 2-bromo-2-(bromomethyl)pentanedinitrile (DBDCB). |
|
(2) |
DBDCB has been evaluated in accordance with Article 16(2) of Directive 98/8/EC of the European Parliament and of the Council (3) for use in product-type 6, in-can preservatives, as described in Annex V to that Directive, which corresponds to product-type 6 as described in Annex V to Regulation (EU) No 528/2012. |
|
(3) |
The Czech Republic was designated as evaluating competent authority and submitted the assessment reports together with its recommendations on 21 January 2009. |
|
(4) |
In accordance with Article 7(2) of Delegated Regulation (EU) No 1062/2014, the opinion of the European Chemicals Agency was formulated on 10 December 2015 by the Biocidal Products Committee, having regard to the conclusions of the evaluating competent authority. |
|
(5) |
According to that opinion, biocidal products of product-type 6 and containing DBDCB may be expected to satisfy the requirements of Article 5 of Directive 98/8/EC, provided that certain specifications and conditions concerning their use are complied with. |
|
(6) |
It is therefore appropriate to approve DBDCB for use in biocidal products of product-type 6, subject to compliance with certain specifications and conditions. |
|
(7) |
Since DBDCB meets the criteria for classification as skin sensitiser category 1 as defined in Annex I to Regulation (EC) No 1272/2008 of the European Parliament and of the Council (4), treated articles treated with or incorporating DBDCB should be labelled appropriately when placed on the market. |
|
(8) |
A reasonable period should be allowed to elapse before an active substance is approved in order to permit interested parties to take the preparatory measures necessary to meet the new requirements. |
|
(9) |
The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Biocidal Products, |
HAS ADOPTED THIS REGULATION:
Article 1
2-bromo-2-(bromomethyl)pentanedinitrile (DBDCB) is approved as an active substance for use in biocidal products of product-type 6, subject to the specifications and conditions set out in the Annex.
Article 2
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 5 July 2016.
For the Commission
The President
Jean-Claude JUNCKER
(1) OJ L 167, 27.6.2012, p. 1.
(2) Commission Delegated Regulation (EU) No 1062/2014 of 4 August 2014 on the work programme for the systematic examination of all existing active substances contained in biocidal products referred to in Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L 294, 10.10.2014, p. 1).
(3) Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market (OJ L 123, 24.4.1998, p. 1).
(4) Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (OJ L 353, 31.12.2008, p. 1).
ANNEX
|
Common Name |
IUPAC Name Identification Numbers |
Minimum degree of purity of the active substance (1) |
Date of approval |
Expiry date of approval |
Product type |
Specific conditions |
||||
|
2-bromo-2-(bromomethyl)pentanedinitrile (DBDCB) |
IUPAC Name: 2-bromo-2-(bromomethyl)pentanedinitrile EC No: 252-681-0 CAS No: 35691-65-7 |
980 g/kg |
1 January 2018 |
31 December 2027 |
6 |
The authorisations of biocidal products are subject to the following conditions:
The placing on the market of treated articles is subject to the following condition: The person responsible for the placing on the market of a treated article treated with or incorporating 2-bromo-2-(bromomethyl)pentanedinitrile (DBDCB) shall ensure that the label of that treated article provides the information listed in the second subparagraph of Article 58(3) of Regulation (EU) No 528/2012. |
(1) The purity indicated in this column was the minimum degree of purity of the active substance used for the evaluation made in accordance with Article 89(1) of Regulation (EU) No 528/2012. The active substance in the product placed on the market can be of equal or different purity if it has been proven technically equivalent with the evaluated active substance.